Radiopharm Theranostics (ASX:RAD) has announced that a study featuring DUNP19 (RAD 502), conducted by Dr David Ulmert and colleagues from the University of California, Los Angeles, is now available in a preprint on BioRxiv.
The paper, 'Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance', demonstrates for the first time how DUNP19 can be used in various cancer models for the detection and targeting of Leucine-Rich Repeat Containing 15 (LRRC15)-expressing cancers.
LRRC15 is a cellular marker and novel therapeutic target in solid tumours and cancers arising from connective tissue.
DUNP19 (RAD 502) is a highly specific monoclonal antibody that targets LRRC15, offering a strong potential for it to be used as a dual-purpose agent for both non-invasive imaging and the theranostic treatment of LRRC15+ aggressive cancers.
Radiopharm’s scientific advisory board member and co-inventor of the DUNP19 platform, Dr David Ulmert, said, "Our transcriptomic analyses of [177Lu]-DUNP19-treated tumours indicate a reduction in pro-tumorigenic mechanisms, including TGFβ-driven LRRC15+ signature associated with resistance to immunotherapy. These findings underscore the potential of radio-theranostic targeting of LRRC15 as a powerful precision medicine platform.”